Beta
Selegiline
medication Under reviewA monoamine oxidase inhibitor (MAOI) used as an adjunct treatment for Parkinson's disease and major depressive disorder.
Research summary
Scientific evidence on selegiline in healthy human subjects is extremely limited, with no randomized controlled trials or substantial studies identified that directly assess its effects, benefits, or safety in this population. Available research overwhelmingly focuses on patients with Parkinson's disease, Alzheimer's disease, or other clinical conditions, leaving a gap in data for healthy individuals. Consensus indicates insufficient evidence to recommend its use for cognitive enhancement, longevity, or general health optimization in healthy adults.
No side effects tracked yet
No side effects have been reported by studies or users for this habit yet.
Research
No studies found yet. Request research to discover relevant studies.
Community updates
No updates yet for this supplement.
Be the first to share your experience!